
Quarterly ResultAug 11, 2026, 04:13 PM
SELLAS Life Sciences Q2 Net Loss $(9.6M); Cash $138.3M
AI Summary
SELLAS Life Sciences Group reported a net loss of $(9.6) million for Q2 2026, an increase from $(6.6) million in Q2 2025, with R&D and G&A expenses rising. For the six months ended June 30, 2026, the net loss was $(18.0) million. The company significantly strengthened its liquidity, ending the quarter with $138.3 million in cash and cash equivalents, primarily due to $82.9 million from warrant exercises. This cash position is expected to fund operations for at least the next twelve months.
Key Highlights
- Q2 2026 net loss was $(9.6) million, compared to $(6.6) million in Q2 2025.
- Cash and cash equivalents increased to $138.3 million as of June 30, 2026.
- Received $82.9 million from warrant exercises in the first six months of 2026.
- R&D expenses rose to $6.3 million in Q2 2026 from $3.9 million in Q2 2025.
- G&A expenses increased to $4.4 million in Q2 2026 from $3.0 million in Q2 2025.
- Arbitration claim dismissed, resulting in a $1.0 million charge for legal fees.
- Equity incentive plan authorized shares increased by 20 million.
Price Impact
More from SLS